These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical evaluation of weekly hepatic arterial infusion chemotherapy in patients with unresectable metastatic liver cancer].
    Author: Kunishima S, Taniguchi H, Koh T, Yamaguchi A, Okamoto K, Shirasu M, Otsuji E, Kitamura K, Hagiwara A, Yamaguchi T, Yamagishi H.
    Journal: Gan To Kagaku Ryoho; 1999 Oct; 26(12):1768-71. PubMed ID: 10560391.
    Abstract:
    Twenty-five cases with unresectable metastatic liver cancers were experienced in our hospital over the past five years who underwent weekly 24-hour continuous hepatic arterial infusion chemotherapy using 5-FU and CBDCA. The response rate was 20%, the median survival was 23 months, and the one/two year overall survival rates averaged 81.3/45.5%. In 77% of patients, this therapy prevented death from hepatic metastases. Moreover, since adverse effects were limited compared with bolus infusion, weekly 24-hour continuous hepatic arterial infusion chemotherapy was thought to be a favorable method.
    [Abstract] [Full Text] [Related] [New Search]